Skip to Content
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • AstraZeneca Gets the Bad News

    After writing about Merck’s successes (so far) in immuno-oncology, it’s time to write about AstraZeneca’s failure. When the rumors started fly… Read More
  • The Keytruda Story

    This is a good history of Keytruda, the Merck immuno-oncology blockbuster, from David Shaywitz. Most big drugs have a tangled history, and this one is certainly… Read More
  • Too Big to Be True

    I recently wrote a column for Chemistry World on the concept of effect size – the readership there is from all sorts of chemistry, so it’s perhaps n… Read More
  • Chaos at AstraZeneca

    What on earth is going on over at AstraZeneca? The company has had plenty of wild ups and downs over the years, and managed to fight off a takeover attempt by P… Read More
Page 1 of 4612345...102030...Last »